Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a Factor?
source: Endocrine Practice
year: 2019
authors: Diker-Cohen T, Duskin-Bitan H, Shimon I, Hirsch D, Akirov A, Tsvetov G, Robenshtok E
summary/abstract:Objective:
Male gender is considered an adverse prognostic factor for remission of Graves disease treatment with antithyroid drugs (ATDs), although published data are conflicting. This often results in early consideration of radioiodine treatment and surgery for men. Our objective was to compare disease presentation and outcome in men versus women treated with ATDs.
Methods:
Retrospective study of 235 patients (64 men, 171 women) with Graves disease who were evaluated for features at presentation and outcome at the end of follow-up between 2010 and 2015.
Results:
Disease presentation was similar in men and women for age at diagnosis (41.4 ± 14 years vs. 40 ± 15 years), duration of follow-up (6.6 ± 7 years vs. 7.7 ± 6 years), rates of comorbid autoimmune diseases, and rate of Graves ophthalmopathy. Smoking was more prevalent in males (31% vs. 15%; P = .009). Free thyroxine and triiodothyronine levels were comparable. ATDs were first-line treatment in all males and in 168 of 171 females, for a median duration of 24 and 20 months, respectively ( P = .55). Remission rates were 47% in men and 58% in women ( P = .14). Males had fewer adverse events (9% vs. 18%) and treatment discontinuation (5% vs. 16%). Disease recurrence was comparable (14% vs. 20%; P = .32), as was requirement for second-line treatment, either radioiodine therapy or thyroidectomy.
Conclusion:
Graves disease presentation is similar in men and women. Men treated with ATDs have high remission rates and similar recurrence rates compared to women, with fewer adverse events and less discontinuation of treatment. ATDs are an attractive first-line treatment for both genders.
DOI: 10.4158/EP-2018-0365
read more full text
myBinderRelated Content
-
TSH-Receptor Autoimmunity in Graves’ Disease After Therapy With Anti-Thyroid Drugs, Surgery, or Radioiodine: A...Introduction: Autoimmunity against the ...
-
A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine PracticeObjective: There are scarce reports reg...
-
Risk Factors for Neonatal Thyroid Dysfunction in Pregnancies Complicated by Graves’ DiseaseObjective: To determine the factors rel...
-
Treatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves’ DiseaseContext: Neutropenia secondary to antit...
-
Impaired Immune Regulation After Radioiodine Therapy for Graves’ Disease and the Protective Effect of Methimaz...Both therapies for Graves' disease (GD),...
-
Drug Versus Radioactive Treatment of Graves’ Disease – Metabolic OutcomesBackground: Weight gain is a common com...
-
Predicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google